Uncategorized
Speaker: Protocol T not applicable in European practice
VIENNA — Results of DRCR.net Protocol T may signal a paradigm shift in the treatment of diabetic macular edema, but are scarcely applicable to the European clinical context, where ranibizumab is marketed and used at a higher 0.5 mg concentration, a specialist told colleagues here.“Protocol T showed superior efficacy of aflibercept, particularly in the group of patients with more severe disease. However, the 0.3 mg ranibizumab concentration used in the study is the one registered for the US market, which is nearly half the concentration we use in Europe,” Francesco (Read more...)